# Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)

Source: https://onco.cc/companies/glenmark/  
OnCo record `glenmark` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Indian company whose trispecific antibody ISB 2001 for multiple myeloma was licensed to AbbVie in 2025 for 700 million dollars upfront, the largest deal for an Indian-discovered cancer drug.

## Summary

Glenmark was founded on 18 November 1977 by Gracias Saldanha in Mumbai. In January 2024 it consolidated oncology discovery into Ichnos Glenmark Innovation (IGI), a venture with its subsidiary Ichnos Sciences, with three molecules in the clinic at launch. In July 2025 IGI licensed ISB 2001, a BCMA x CD38 x CD3 trispecific T-cell engager in phase 1 for relapsed or refractory multiple myeloma, to AbbVie for 700 million dollars upfront and up to 1.225 billion dollars in milestones plus royalties; AbbVie took North America, Europe, Japan and Greater China and Glenmark kept India and emerging markets. In 2025 Glenmark also in-licensed the HER2 ADC trastuzumab rezetecan from Hengrui (a deal valued at up to 1.1 billion dollars) and the EGFR inhibitor aumolertinib from Hansoh for several regions.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Mumbai
- Type: pharma
- Website: https://www.glenmarkpharma.com
- Ticker: GLENMARK.NS

## Sources

- Official website: https://www.glenmarkpharma.com

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD38](https://onco.cc/targets/cd38/), [HER2](https://onco.cc/targets/her2/)
- drugs: [ISB 2001](https://onco.cc/drugs/isb-2001/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- bottlenecks: [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)

---
JSON: https://onco.cc/api/v1/entities/glenmark.json